Sanofi (SAN) News Today €83.94 -0.22 (-0.26%) As of 10/14/2025 Add Compare Share Share Headlines Stock AnalysisChartHeadlinesSustainabilityBuy This Stock SAN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period COPD Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Amgen, Synairgen, AstraZeneca, Sanofi, Organicell Regenerative ...October 14 at 10:04 PM | theglobeandmail.comSanofi’s Promising COPD Study: Lunsekimig’s Potential ImpactOctober 14 at 12:31 PM | tipranks.comSanofi’s New COPD Treatment Study: A Potential Game-Changer?October 14 at 12:31 PM | tipranks.comSanofi’s New Study on SAR446597: A Potential Game-Changer for Age-related Macular DegenerationOctober 10, 2025 | tipranks.comHow Positive Phase II Results for AlphaMedix at Sanofi (ENXTPA:SAN) Have Changed Its Investment StoryOctober 10, 2025 | finance.yahoo.comSanofi ModulusOctober 9, 2025 | time.comTBIOVAXYS APPOINTS FORMER SANOFI VACCINES EXECUTIVE TO BOARD OF DIRECTORSOctober 9, 2025 | finance.yahoo.comSanofi AlphaMedix Study Hits Key Milestones In Phase 2 StudyOctober 8, 2025 | benzinga.comBioVaxys Strengthens Board with Former Sanofi ExecutiveOctober 8, 2025 | tipranks.comBenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci’s ASCEND PlatformOctober 8, 2025 | financialpost.comFNovavax Transfers EU Vaccine Rights to SanofiOctober 7, 2025 | tipranks.comRevvity, Sanofi team on early Type 1 detection; Kihealth raises funds for diabetes test rolloutOctober 7, 2025 | yahoo.comSanofi: Undervalued 2026 Pipeline, And Solid Results (Rating Upgrade)October 5, 2025 | seekingalpha.comSanofi (SNY) Invests $625 Million in Sanofi VenturesOctober 5, 2025 | insidermonkey.comSanofi’s Phase 3 Study on Duvakitug: A Potential Game-Changer for Ulcerative ColitisOctober 2, 2025 | tipranks.comSanofi’s Promising Phase 3 Study on Duvakitug for Crohn’s DiseaseOctober 2, 2025 | tipranks.comSanofi’s Phase 3 Study on Duvakitug: A Potential Game-Changer for Crohn’s Disease TreatmentOctober 2, 2025 | tipranks.comSanofi’s Promising Phase 3 Study on Duvakitug for Ulcerative ColitisOctober 2, 2025 | tipranks.comSanofi’s New Study on Beyfortus: A Closer Look at Market ImplicationsOctober 1, 2025 | tipranks.comEU carries out antitrust inspection at premises of pharma SanofiOctober 1, 2025 | msn.comBrussels raids Sanofi in flu vaccine antitrust probeOctober 1, 2025 | ft.comSanofi says under investigation by European Commission over vaccinesOctober 1, 2025 | msn.comSanofi Raided by EU in ‘Disparagement’ Antitrust CaseSeptember 30, 2025 | msn.comNovavax allows Sanofi to use Matrix-M adjuvant for pandemic flu candidateSeptember 30, 2025 | seekingalpha.comSanofi Consumer Healthcare India Initiates Postal Ballot for Related Party TransactionsSeptember 30, 2025 | tipranks.comAssessing Sanofi’s Share Price After 7% Drop and Latest FDA Approval NewsSeptember 29, 2025 | finance.yahoo.comSanofi set to offer insulin products at $35 per month for all US patientsSeptember 26, 2025 | msn.comSanofi making all insulin meds available for $35 a month in USSeptember 26, 2025 | seekingalpha.comSanofi Expanding Insulin Savings Program to Insured PatientsSeptember 26, 2025 | marketwatch.comSanofi's new US HQ offers transit-accessible hospitality in New JerseySeptember 26, 2025 | msn.comRegeneron Receives FDA Approval to Extend Evkeeza Indication for Children Aged 1 to Under 5 with Homozygous HypercholesterolemiaSeptember 26, 2025 | quiverquant.comQSanofi India Announces Key Management ChangeSeptember 25, 2025 | tipranks.comImmuneering Corporation Announces Proposed Underwritten Public Offering of Class A Common Stock and Private Placement with SanofiSeptember 24, 2025 | quiverquant.comQSanofi’s Pediatric Study on Unexplained Splenomegaly: Key Insights for InvestorsSeptember 23, 2025 | tipranks.comSanofi’s Dupixent Advances in EU with Positive CHMP OpinionSeptember 22, 2025 | tipranks.comFDA Delays Key Sanofi Multiple Sclerosis Drug DecisionSeptember 22, 2025 | benzinga.comRegeneron, Sanofi announce CHMP opinion recommending Dupixent approvalSeptember 22, 2025 | msn.comSanofi Sees Progress for Hives Treatment in EU, Longer U.S. Review for MS DrugSeptember 22, 2025 | marketwatch.comPress Release: Sanofi and Regeneronâs Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinionSeptember 22, 2025 | markets.businessinsider.comRegeneron and Sanofi Announce Positive CHMP Opinion for Dupixent® in Treating Chronic Spontaneous Urticaria in the European UnionSeptember 21, 2025 | quiverquant.comQEADV 25: Sanofi’s brivekimig success in Phase IIa HS trialSeptember 17, 2025 | msn.comSanofi Reports Early Brivekimig Data, Signals Strong Efficacy And Good TolerabilitySeptember 17, 2025 | benzinga.comSanofi’s Tzield Gains Approval in China for Type 1 DiabetesSeptember 17, 2025 | tipranks.comSanofi (SNY) Fell on Tariff UncertaintySeptember 17, 2025 | insidermonkey.comNurix Therapeutics Advances GS-6791 into Clinical Testing for Inflammatory Diseases with Preclinical Data Presented at EADV CongressSeptember 17, 2025 | quiverquant.comQSanofi’s Promising Growth Prospects: Buy Rating Backed by Brivekimig and Tolebrutinib PotentialSeptember 17, 2025 | tipranks.comPress Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a studySeptember 17, 2025 | markets.businessinsider.comLeerink Partners Maintains a Buy Rating on Sanofi (SNY)September 16, 2025 | finance.yahoo.comHow Paul Hudson runs Sanofi’s AI ‘Fight Club’September 12, 2025 | finance.yahoo.comMetastatic Non-Small Cell Lung Cancer Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and ...September 11, 2025 | theglobeandmail.com Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SAN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SAN Media Mentions By Week SAN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SAN News Sentiment▼0.500.72▲Average Medical News Sentiment SAN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SAN Articles This Week▼77▲SAN Articles Average Week Get the Latest News and Ratings for SAN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Sanofi and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Deutsche Bank Aktiengesellschaft News Today Bayer Aktiengesellschaft News Today Fielmann Group News Today Fresenius SE & Co. KGaA News Today Genfit News Today Sartorius Stedim Biotech News Today Siemens Healthineers News Today Merck KGaA News Today Sartorius Aktiengesellschaft News Today Fresenius Medical Care News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (EPA:SAN) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanofi Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanofi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
